Business & Finance

DNA-focused biopharmaceutical company announces fourth quarter, year end results

Published in Vaccine Weekly, March 16th, 2005

Vical Incorporated (VICL) reported revenues of $5 million for the fourth quarter of 2004, compared with revenues of $1.7 million for the fourth quarter of the prior year. The increase in revenues was primarily the result of the timing of contract manufacturing shipments.

Revenues for the full year 2004 were $14.5 million compared with $8.1 million for the full year 2003. Results for the year reflected higher contract revenues for DNA vaccine supplies, a milestone payment under the company's agreement with Centelion SAS, formerly Gencell SAS, a wholly owned subsidiary of Aventis Pharma SA, and increased grant funding for the company's cytomegalovirus (CMV) vaccine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-03-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry